While we connect patients with licensed providers who can prescribe treatments like Compounded Semaglutide or Compounded Tirzepatide, we emphasize that these tools work best when paired with a thoughtful, personalized lifestyle plan
Innovation Directions Rather than pursuing oral convenience, leading companies focus on injectable innovation: Extended-release formulations reducing injection frequency (monthly, quarterly) Multi-target mechanisms enhancing efficacy beyond single GLP-1 activation Combination therapies addressing multiple obesity pathways simultaneously Improved delivery devices enhancing patient experience with injections Amgens monthly MariTide exemplifies this approach, achieving 20% weight loss with just 12 annual injections versus 52 for weekly alternatives
Cintia Cercato declares having received consulting honoraria from Novo Nordisk, Eli Lilly, Merck, Brace Pharma and Eurofarma
Gallagher EJ, Sun H, Kornhauser C, Tobin-Hess A, Epstein S, Yakar S, et al